Investment17 Jan 2024, 08:55 pm
NATCO Pharma invests $2M in Cellogen Therapeutics
AI Summary
NATCO Pharma Limited has invested around USS 2 million in Cellogen Therapeutics Private Limited, a Delhi-based biotech startup focused on cell and gene therapy solutions. The investment will support Cellogen's R&D programs, including its CAR T cell therapy program and gene therapy program for transfusion-dependent thalassemia and sickle cell disease.,
Key Highlights
- NATCO Pharma invests $2M in Cellogen Therapeutics
- Cellogen Therapeutics focuses on cell and gene therapy solutions
- CAR T cell therapy program and gene therapy program for transfusion-dependent thalassemia and sickle cell disease